


Disclaimer: This algorithm has been developed for MD Anderson using a multidisciplinary approach considering circumstances particular to MD Anderson's specific patient population, services and structure, and clinical information. This is not intended to replace the independent medical or professional judgment of physicians or other health care providers in the context of individual clinical circumstances to determine a patient's care. This algorithm should not be used to treat pregnant women.

Note: Consider clinical trials as treatment options for eligible patients. Leukemia patients should be referred and treated at a comprehensive cancer center.

PATIENT PRESENTATION²

TREATMENT

SURVEILLANCE



IPSS = International Prognostic Scoring System
 IPSS-R = revised International Prognostic Scoring System

¹ Age ≥ 18 years

² See [Physical Activity](#), [Nutrition](#), and [Tobacco Cessation](#) algorithms; ongoing reassessment of lifestyle risks should be a part of routine clinical practice

³ MDS risk is calculated utilizing the IPSS or IPSS-R score, which includes percent of blast, cytogenetics (consider [MD Anderson approved biomarkers](#)), and number of cytopenias

⁴ See [Leukemia Clinical Trials](#)

Disclaimer: This algorithm has been developed for MD Anderson using a multidisciplinary approach considering circumstances particular to MD Anderson's specific patient population, services and structure, and clinical information. This is not intended to replace the independent medical or professional judgment of physicians or other health care providers in the context of individual clinical circumstances to determine a patient's care. This algorithm should not be used to treat pregnant women.

SUGGESTED READINGS

- Bowen, D., Culligan, D., Jowitt, S., Kelsey, S., Mufti, G., Oscier, D., & Parker, J. (2003). Guidelines for the diagnosis and therapy of adult myelodysplastic syndromes. *British Journal of Haematology*, 120(2), 187–200. <https://doi.org/10.1046/j.1365-2141.2003.03907.x>
- Fenaux, P., Mufti, G., Hellstrom-Lindberg, E., Santini, V., Finelli, C., Giagounidis, A., . . . Silverman, L. (2009). Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: A randomised, open-label, phase III study. *Lancet Oncology*, 10(3), 223–232. [https://doi.org/10.1016/S1470-2045\(09\)70003-8](https://doi.org/10.1016/S1470-2045(09)70003-8)
- Fenaux, P., Platzbecker, U., Mufti, G., Garcia-Manero, G., Buckstein, R., Santini, V., . . . List, A. (2020). Luspatercept in patients with lower-risk myelodysplastic syndromes. *The New England Journal of Medicine*, 382(2), 140–151. <https://doi.org/10.1056/nejmoa1908892>
- Kantarjian, H., Issa, J. P., Rosenfeld, C., Bennett, J., Albitar, M., Dipersio, J., . . . Saba, H. (2006). Decitabine improves patient outcomes in myelodysplastic syndromes: Results of a phase III randomized study. *Cancer*, 106(8), 1794–1803. <https://doi.org/10.1002/cncr.21792>
- List, A., Dewald, G., Bennett, J., Giagounidis, A., Raza, A., Feldman, E., . . . Knight, R. (2006). Lenalidomide in the Myelodysplastic Syndrome with Chromosome 5q Deletion. *The New England Journal of Medicine*, 355(14), 1456–1465. <https://doi.org/10.1056/NEJMoa061292>
- Mufti, G., Bennett, J., Goasguen, J., Bain, B., Baumann, I., Brunning, R., . . . Yoshimi, A. (2008). Diagnosis and classification of myelodysplastic syndrome: International Working Group on Morphology of Myelodysplastic Syndrome (IWGM-MDS) consensus proposals for the definition and enumeration of myeloblasts and ring sideroblasts *Haematologica*, 93(11), 1712–1717. <https://doi.org/10.3324/haematol.13405>
- National Comprehensive Cancer Network. (2020). *Myelodysplastic Syndromes* (NCCN Guideline Version 2.2020). Retrieved from https://www.nccn.org/professionals/physician_gls/pdf/mds.pdf.
- Oliansky, D., Antin, J., Bennett, J., Joachim Deeg, H., Engelhardt, C., Heptinstall, K., . . . Hahn, T. (2009). The Role of Cytotoxic Therapy with Hematopoietic Stem Cell Transplantation in the Therapy of Myelodysplastic Syndromes: An Evidence-Based Review. *Biology of Blood and Marrow Transplantation*, 15(2), 137–172. <https://doi.org/10.1016/j.bbmt.2008.12.003>
- Santini, V., Alessandrino, P., Angelucci, E., Barosi, G., Billio, A., Di Maio, M., . . . Tura, S. (2010). Clinical management of myelodysplastic syndromes: Update of SIE, SIES, GITMO practice guidelines. *Leukemia Research*, 34(12), 1576–1588. <https://doi.org/10.1016/j.leukres.2010.01.018>
- Tefferi, A., & Vardiman, J. (2009). Myelodysplastic Syndromes. *The New England Journal of Medicine*, 361(19), 1872–1885. <https://doi.org/10.1056/NEJMra0902908>
- Valent, P., Horny, H., Bennett, J., Fonatsch, C., Germing, U., Greenberg, P., . . . Wells, D. (2007). Definitions and standards in the diagnosis and treatment of the myelodysplastic syndromes: Consensus statements and report from a working conference. *Leukemia Research*, 31(6), 727–736. <https://doi.org/10.1016/j.leukres.2006.11.009>

Disclaimer: This algorithm has been developed for MD Anderson using a multidisciplinary approach considering circumstances particular to MD Anderson's specific patient population, services and structure, and clinical information. This is not intended to replace the independent medical or professional judgment of physicians or other health care providers in the context of individual clinical circumstances to determine a patient's care. This algorithm should not be used to treat pregnant women.

DEVELOPMENT CREDITS

This practice algorithm is based on majority expert opinion of the Leukemia Center Faculty workgroup at the University of Texas MD Anderson Cancer Center. It was developed using a multidisciplinary approach that included input from the following:

Yesid Alvarado, MD (Leukemia)	Michael Keating, MD (Leukemia)
Michael Andreeff, PhD, MD (Leukemia)	Marina Konopleva, PhD, MD (Leukemia)
Kapil Bhalla, MD (Leukemia)	Steven Kornblau, MD (Leukemia)
Gautam Borthakur, MBBS (Leukemia)	Lucia Masarova, MD (Leukemia)
Prithviraj Bose, MD (Leukemia)	Deborah M. McCue, PharmD (Pharmacy Clinical Programs)
Jan Burger, MD (Leukemia)	Guillermo Montalban-Bravo, MD (Leukemia)
Naval Daver, MD (Leukemia)	Maro Ohanian, DO (Leukemia)
Courtney DiNardo, MD (Leukemia)	Naveen Pemmaraju, MD (Leukemia)
Alessandra Ferrajoli, MD (Leukemia) [‡]	Farhad Ravandi-Kashani, MD (Leukemia)
Emil Freireich, MD (Leukemia)	Mary Beth Rios, RN (Leukemia) [‡]
Wendy Garcia, BS [♦]	Koji Sasaki, MD (Leukemia)
Guillermo Garcia-Manero, MD (Leukemia) [‡]	Nicholas Short, MD (Leukemia)
Ghayas Issa, MD (Leukemia)	Koichi Takahashi, MD (Leukemia)
Elias Jabbour, MD (Leukemia)	Philip Thompson, MBBS (Leukemia)
Nitin Jain, MBBS (Leukemia)	Srdan Verstovsek, MD (Leukemia)
Tapan Kadia, MD (Leukemia)	Mary Lou Warren, DNP, APRN, CNS-CC [♦]
Hagop M. Kantarjian, MD (Leukemia) [‡]	William Wierda, PhD, MD (Leukemia)
	Musa Yilmaz, MD (Leukemia)

[‡] Core Development Leads

[♦] Clinical Effectiveness Development Team